Payment overview · 2025
General Payments
$947.04
45 reported records · 13 companies
Healthcare provider profile · identity verified
Daniela Turacova, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · EAST PROVIDENCE, RI · NPI 1972685170
Verified facts
What the public records show
CMS Open Payments records show Daniela Turacova, M.D. received $947.04 in general payments during 2025 across 45 reported records.
ABBVIE INC. accounted for 34.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $329.17 | 34.8% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $228.10 | 24.1% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $108.61 | 11.5% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.52 | 6.2% | 6 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $50.03 | 5.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.68 | 2.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.01 | 2.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.79 | 2.6% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $24.64 | 2.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.59 | 2.1% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $17.45 | 1.8% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.82 | 1.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.63 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $947.04 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $182.42 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $166.55 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $108.61 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $105.54 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $93.80 | 7 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $68.82 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $58.52 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $54.56 | 3 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $50.03 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $46.11 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.71 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $26.68 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.01 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.15 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 335 | 83 |
| Prednisone | Prednisone | 320 | 204 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 305 | 46 |
| Omeprazole | Omeprazole | 304 | 86 |
| Fluticasone Propionate | Fluticasone Propionate | 287 | 140 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 57 |
| Meloxicam | Meloxicam | 245 | 69 |
| Metformin Hcl | Metformin Hcl | 207 | 50 |
| Azithromycin | Azithromycin | 189 | 143 |
| Gabapentin | Gabapentin | 189 | 47 |
| Montelukast Sodium | Montelukast Sodium | 185 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 184 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 173 | 46 |
| Alprazolam | Alprazolam | 167 | 28 |
| Furosemide | Furosemide | 166 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 162 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 157 | 130 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 50 |
| Lisinopril | Lisinopril | 154 | 42 |
| Simvastatin | Simvastatin | 150 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 33 |
| Losartan Potassium | Losartan Potassium | 119 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 30 |
| Trazodone Hcl | Trazodone Hcl | 106 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 105 | 16 |
| Ibuprofen | Ibuprofen | 95 | 40 |
| Ventolin Hfa | Albuterol Sulfate | 88 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 84 | 48 |
| Eliquis | Apixaban | 80 | 12 |
| Clonazepam | Clonazepam | 77 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 36 |
| Pregabalin | Pregabalin | 77 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 14 |
| Diazepam | Diazepam | 75 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 75 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 15 |
| Allopurinol | Allopurinol | 70 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 67 | 21 |
| Tramadol Hcl | Tramadol Hcl | 63 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 41 |
| Glimepiride | Glimepiride | 58 | 13 |
| Lorazepam | Lorazepam | 58 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 58 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Atenolol | Atenolol | 48 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 15 |
| Meclizine Hcl | Meclizine Hcl | 45 | 21 |
| Nystatin | Nystatin | 43 | 14 |
| Carvedilol | Carvedilol | 41 | 11 |
| Naproxen | Naproxen | 40 | 13 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 31 | 13 |
| Ozempic | Semaglutide | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 20 |
| Temazepam | Temazepam | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | 21 |
| Ofloxacin | Ofloxacin | 27 | 23 |
| Valacyclovir | Valacyclovir Hcl | 27 | 12 |
| Amoxicillin | Amoxicillin | 26 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Erythromycin | Erythromycin Base | 25 | 23 |
| Estradiol | Estradiol | 25 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Clarithromycin | Clarithromycin | 21 | 16 |
| Colchicine | Colchicine | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Crestor | Rosuvastatin Calcium | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Permethrin | Permethrin | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Unithroid | Levothyroxine Sodium | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $947.04 · 45 records | ABBVIE INC. | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CREON, FARXIGA, LINZESS, MOUNJARO, NURTEC ODT, OPSUMIT, PURIFIED CORTROPHIN GEL, QULIPTA, TRELEGY ELLIPTA, UBRELVY, UPTRAVI, VOQUEZNA, VRAYLAR, WAKIX, Xhance, ZAVZPRET, ZENPEP, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error